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Abstract
Introduction: Epratuzumab, a humanized anti-CD22 monoclonal antibody, is under investigation as a therapeutic
antibody in non-Hodgkin’s lymphoma and systemic lupus erythematosus (SLE), but its mechanism of action on
B-cells remains elusive. Treatment of SLE patients with epratuzumab leads to a reduction of circulating CD27
negative
B-cells, although epratuzumab is weakly cytotoxic to B-cells in vitro. Therefore, potential effects of epratuzumab on
adhesion molecule expression and the migration of B-cells have been evaluated.
Methods: Epratuzumab binding specificity and the surface expression of adhesion molecules (CD62L, b7 integrin
and b1 integrin) after culture with epratuzumab was studied on B-cell subsets of SLE patients by flow cytometry. In
addition, in vitro transwell migration assays were performed to analyze the effects of epratuzumab on migration
towards different chemokines such as CXCL12, CXCL13 or to CXCR3 ligands, and to assess the functional
consequences of altered adhesion molecule expression.
Results: Epratuzumab binding was considerably higher on B-cells relative to other cell types assessed. No binding
of epratuzumab was observed on T-cells, while weak non-specific binding of epratuzumab on monocytes was
noted. On B-cells, binding of epratuzumab was particularly enhanced on CD27
negative B-cells compared to
CD27
positive B-cells, primarily related to a higher expression of CD22 on CD27
negative B-cells. Moreover, epratuzumab
binding led to a decrease in the cell surface expression of CD62L and b7 integrin, while the expression of b1
integrin was enhanced. The effects on the pattern of adhesion molecule expression observed with epratuzumab
were principally confined to a fraction of the CD27
negative B-cell subpopulation and were associated with enhanced
spontaneous migration of B-cells. Furthermore, epratuzumab also enhanced the migration of CD27
negative B-cells
towards the chemokine CXCL12.
Conclusions: The current data suggest that epratuzumab has effects on the expression of the adhesion molecules
CD62L, b7 integrin and b1 integrin as well as on migration towards CXCL12, primarily of CD27
negative B-cells.
Therefore, induced changes in migration appear to be part of the mechanism of action of epratuzumab and are
consistent with the observation that CD27
negative B-cells were found to be preferentially reduced in the peripheral
blood under treatment.
Introduction
Systemic lupus erythematosus (SLE) is a very heteroge-
neous autoimmune disease with various clinical manifes-
tations and different immune abnormalities, including
the production of a plethora of autoantibodies, deposi-
tion of immune complexes in various organs, and poten-
tial organ failure [1]. In patients with SLE, disturbances
of B-cells in the peripheral blood (including an increase
of CD27
negative transitional B-cells and CD27
positive
B-cells as well as enhanced CD27
high plasmablasts),
abnormalities of humoral immunity, immune complex
formation, complement activation as well as experiences
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key role for B-cells in the pathogenesis of this disease.
Hence, immunotherapy targeting B-cells is currently of
great interest with the promise to improve current treat-
ments of SLE. In this context, epratuzumab, a huma-
nized monoclonal IgG1 antibody (mAb) that targets the
B-cell surface molecule CD22, has been explored in an
early clinical trial [2] and more recently in a phase IIb
randomized clinical study which showed a treatment
advantage with epratuzumab over placebo of around
25% at week 12 [3].
CD22, a 140 kDa transmenbrane type 1 protein, also
called Sialic acid-binding Ig-like lectin 2 (Siglec-2) or
B-lymphocyte cell adhesion molecule (BL-CAM), is a
member of the Siglec family that binds to a2-6-linked
sialic acids on glycoproteins. These ligands for CD22 are
widely expressed on different cell types [4] (co called
trans glycoprotein ligands) including B-cells (where
CD22 will also bind cis glycoprotein ligands).
CD22 is differentially expressed during B-cell differen-
tiation. At early developmental stages, such as pre-
B-cells, CD22 is expressed intracellularly and appears on
the surface on immature B-cells reaching the highest
surface expression levels on mature B-cells and declin-
ing substantially during final maturation into plasma
cells [5-7]. Although Stathish et al. also described the
expression of CD22 on murine primary T-cells [8],
CD22 has not been detected on human T-cells and
monocytes [4].
Interestingly, CD22 has two different functions on
B-cells. It is well known as a negative regulatory mole-
cule of the B-cell antigen receptor (BCR) signal leading
to inhibition of B-cell activation by phosphorylation of
the protein tyrosine phosphatase SHP-1 (Src homology
region 2 domain-containing phosphatase 1) via the
immunoreceptor tyrosine-based inhibitory motifs
(ITIMs) contained in the cytoplasmic tail [9]. Moreover,
CD22 is also considered as an adhesion receptor for the
homing of re-circulating IgD
positive B-cells in the bone
marrow via the expression of CD22 ligand on bone mar-
row sinusoidal endothelium [10-12].
The functional diversity of CD22 has implications for
the hitherto unknown mechanism of action by epratuzu-
mab and is of interest. Initial treatment with this mAb
in patients with SLE showed a significant decrease of
BILAG (British Isles Lupus Assessment Group) scores
above 50% [2]. In this study, a significant reduction of
peripheral B-cells was also observed in SLE patients
who were treated with epratuzumab, primarily a 30%
reduction of CD27
negative B-cells comprising transitional
and naïve B-cells [2,13]. The reason for the reduction in
B-cell numbers remains unknown.
In this context, earlier studies reported that epratuzu-
mab, in contrast to rituximab, was weakly cytotoxic for
B-cells since it could induce modest antibody-depen-
dent cellular cytotoxicity (ADCC) and no complement-
dependent cytotoxicity (CDC) in vitro;h o w e v e r ,
epratuzumab modulates exaggerated activation and
proliferation of B-cells from SLE patients following
CpG, BCR and CD40L stimulation [13-15]. Epratuzu-
mab binds to non-ligand binding epitopes on CD22
and provokes phosphorylation of CD22 [16,17].
While epratuzumab appears to have only a very lim-
ited capacity to induce direct apoptosis [13,14] via CDC
and ADCC, the apparent reduction of peripheral blood
CD27
negative B-cells under therapy led to the hypothesis
that triggering CD22 could modulate B-cell migration
possibly resulting in reduced CD27
negative B-cell counts
in the blood. Since cell trafficking is a multistep process
involving the concerted interaction of cell adhesion
molecules binding to their respective ligands as well as
chemokine-regulated migration pathways, our study was
designed to assess the effects of epratuzumab on the
expression of a range of adhesion molecules (CD62L, b1
integrin and b7 integrin) and migration towards
CXCL12, CXCL13 and a number of CXCR3 ligands
(CXCL9, 10 and 11) on peripheral blood mononuclear
cells (PBMCs) from SLE patients. These three adhesion
molecules and their ligands are critical for B-cell traf-
ficking. CD62L (L-selectin) is involved in the homing of
B-cells preferentially into peripheral lymphoid tissues
through high endothelial venules (HEV). The b7 integrin
associated with its a4 integrin partner (to form the
a4b7 integrin) is responsible for the homing of lympho-
cytes preferentially into mucosal immune tissues via the
ligand mucosal addressin cell adhesion molecule-1
(MAdCAM-1) on large endothelial venules, while the
a4b1 integrin, a receptor for fibronectin and vascular
cell adhesion molecule-1 (VCAM-1), is preferentially
involved in the homing and retention of lymphocytes
and hematopoietic stem cells to the bone marrow and
the trafficking of leukocytes [18-23]. Therefore, we
addressed the potential influence of epratuzumab on the
cell surface expression of adhesion molecules and cell
migration in vitro which are important B-cell functions.
The results from the current study demonstrate speci-
fic binding of epratuzumab on B-cells. Additionally, we
observed greater binding of epratuzumab on CD27
nega-
tive B-cells which was related to the expression of CD22
which was higher on CD27
negative B-cells compared to
CD27
positive B-cells. Epratuzumab binding to CD27
negative
B-cells induced a significant reduction of CD62L and b7
integrin surface expression, while b1i n t e g r i nw a su p -
regulated. Functionally, CD27
negative B-cells cultured
with epratuzumab showed enhanced spontaneous migra-
tion across fibronectin coated filters. Finally, epratuzu-
mab incubation was found to enhance the migration
towards CXCL12 of CD27
negative B-cells, but not of
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positive B-cells. These results suggest that epratuzu-
mab is able to modulate B-cell migration and adhesion
molecule expression, processes that potentially contri-
bute to its mechanism of action in SLE.
Materials and methods
Subjects
After informed consent was obtained for the protocol
approved by the Institutional Review Board at the Char-
ité - University Hospitals, Berlin, SLE patients were
enrolled in the study. All patients fulfilled the American
College of Rheumatology ACR criteria, revised in 1982
[24]. Thirty SLE patients (28 females, 2 males), 39.1 ±
13.9 years old were studied. PBMCs were prepared from
30 to 40 mL anti-coagulated blood by density gradient
centrifugation over ficoll-paque (Amersham Pharmacia
Biotech, Uppsala, Sweden), and then washed twice with
phosphate-buffered saline (PBS) supplemented with
0.05% (w/v) of bovine serum albumin (BSA, Sigma-
Aldrich, Seelze, Germany).
Adhesion molecule surface expression after epratuzumab
incubation
To monitor changes of adhesion molecule surface
expression (b1 integrin, b7 integrin and CD62L) after
epratuzumab incubation, freshly isolated PBMCs were
incubated with 10 μg/mL of epratuzumab in RPMI 1640
medium (Gibco BRL, Karlsruhe, Germany) supplemen-
ted with 0.5% (w/v) BSA for 90 minutes at 37°C and 5%
CO2. After incubation, the PBMCs were washed in cold
PBS-BSA 0.05% (w/v) and then stained on ice for FACS
analysis as described below.
Fibronectin-dependent chemotaxis
Fibronectin-dependent chemotaxis was assessed using
transwell migration plates (5.0 μm pores, Corning Life
Sciences, Acton, MA, USA) coated with 10 μg/mL of
fibronectin (Invitrogen, Carlsbad, CA, USA), a ligand for
the b1 integrin [25].
1×1 0
6 PBMCs were incubated with or without 10
μg/mL of epratuzumab and allowed to migrate for 90
minutes at 37°C and 5% CO2 using transwell migration
assays. Migration towards CXCL12 (50 nM) (stromal
cell-derived factor, SDF1) or CXCL13 (250 nM) (B-cell
homing chemokine, BLC or also B-cell attracting che-
mokine 1, BCA1) or to a mix of CXCR3 ligands
(CXCL9 (250 nM) (monokine induced by gamma inter-
feron, MIG), CXCL10 (300 nM) (interferon inducible
protein 10, IP10) and CXCL11 (10 nM) (interferon-
inducible T-cell alpha chemoattractant, I-TAC)) were
studied by adding the different chemokines to the lower
chamber in RPMI 1640 supplemented with 0.5% (w/v)
BSA as described previously [26]. All chemokines were
from R&D Systems, Minneapolis, MN, USA.
At the end of the incubation, migrated and non-
migrated cells were harvested from the lower and upper
compartments, respectively, counted and phenotyped by
FACS as described below. The results were expressed as
percentage of migrated B-cells using the following for-
mula: number of migrated B-cells/(number of non
migrated B-cells + number of migrated B-cells) × 100.
To assess spontaneous migration, controlled migra-
tions were performed without using any chemokine gra-
dient. The B-cells that migrated independently of the
chemokine gradient were considered to have functional
b1 integrin.
FACS analysis
Staining of freshly isolated PBMCs and treated PBMCs
was performed as described previously [26]. The fol-
lowing antibodies were used: CD3-Pacific Blue (PB) or
H7-allophycocyanin (APC) (BD, Clone UCHT1),
CD14-PB or H7-APC (BD, Clone m5e2), CD19-phy-
coerythrin-cyanin 7 (PE-Cy7) (BD, Clone SJ 25C1),
CD20-peridin chlorophyll protein (PerCP) (BD, Clone
L27), CD62L-fluorescein isothiocyanate (FITC) (Clone
145/15, Miltenyi Biotec, Auburn, CA, USA), CD27-
cyanin 5 (Cy5) (clone 2E4, kindly provided by Rene
Van Lier, University of Amsterdam, The Netherlands),
b7 integrin-phycoerythrin (PE) (BD, clone FIB504), b1
integrin-PE (BD, clone MAR4), CD22-PE (BD, clone
S-HCL-1) and epratuzumab IgG and F(ab’)2 fragment
of epratuzumab (provided by UCB, Slough, UK).
T-cells, B-cells and monocytes were gated using their
scatter properties and stained for CD3, CD19 or
CD14. Analysis was performed with a Becton Dickin-
son Canto II machine and data were analyzed using
FCS Express 3.0 software (DeNovo Software, Los
Angeles, CA, USA) or using FlowJo™ software (TreeS-
tar, Ashland, OR, USA).
Binding specificity of epratuzumab experiments
A total of 1 to 2 × 10
6 freshly isolated PBMCs were pre-
incubated in 50 μl of PBS/0.05% (w/v) BSA with or
without 8.8 μg of unlabeled F(ab’)2 fragment of epratu-
zumab for 10 minutes on ice, then 1 μg of PE-labeled
epratuzumab, CD3/14 H7-APC, CD27-Cy5, CD20-
PerCP and CD19-PE-Cy7 were added to the PBMCs.
After 15 minutes of staining in the dark, the PBMCs
were washed two times in cold PBS/0.05% (w/v) BSA
and then analyzed by FACS.
Statistical analysis
Unpaired data sets were compared using the nonpara-
metric Mann-Whitney U-test and paired data were ana-
lyzed using the Wilcoxon test with GraphPad Prism4
software (GraphPad, San Diego, CA, USA). A P-value
less than 0.05 was considered significant (* P < 0.05;
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Results
Enhanced CD22 expression and epratuzumab binding to
CD27
negative B-cells from SLE patients
In order to delineate more thoroughly the effects of
epratuzumab in relation to its target CD22, the binding
capacity of epratuzumab to specific leukocyte subsets
such as T-cells, B-cells and monocytes was studied.
Therefore, FACS analyses were performed on PBMCs
from SLE patients with PE-labelled epratuzumab. Clear
binding of epratuzumab on B-cells was shown, whereas
no epratuzumab binding was observed on T-cells.
Interestingly, epratuzumab appeared to bind to mono-
cytes (Figure 1a). To further evaluate the binding spe-
cificities of epratuzumab, we performed blocking
experiments where cells were incubated with unlabeled
F(ab’)2 fragments of epratuzumab for 10 minutes on
ice (Figure 1b, grey histogram) and then stained with
PE-labeled epratuzumab (Figure 1b, black line histo-
gram). We observed inhibition of epratuzumab binding
after incubation with unlabeled F(ab’)2 fragments of
epratuzumab on B-cells (Figure 1b, left graph). From
these experiments, we conclude that epratuzumab
binds specifically to B-cells via CD22 without a
requirement for Fc fragment binding. T-cells did not
show any epratuzumab binding and were subsequently
used as negative control. Notably, we did not observe
any significant inhibition of epratuzumab binding on
monocytes after incubation with unlabeled F(ab’)2 frag-
ment of epratuzumab (Figure 1b), suggesting that the
binding of this antibody to monocytes is likely related
to the Fc moiety. Furthermore, experiments with a
commercially available mouse anti-human CD22 anti-
body, clone S-HCL-1, targeting a different epitope on
CD22 than epratuzumab [16] did not show any bind-
ing to either monocytes or T cells (data not shown).
Figure 1 The binding capacity of epratuzumab on different PBMCs obtained from SLE patients. (a) FACS analyses were performed on
PBMCs from SLE patients using PE- labeled epratuzumab. Representative histogram of the differential binding of epratuzumab on T-cells
(CD3
positive, dotted line), monocytes (CD14
positive, black histogram) and B-cells (CD19
positive, black line). (b) PBMCs were incubated with (grey
histogram) or without (black line) unlabelled F(ab’)2 epratuzumab fragment for 10 minutes at 4°C. PBMCs were then stained with PE labeled-
epratuzumab, and epratuzumab binding analyzed on B-cells, T-cells and monocytes (n = 3). Representative histogram of epratuzumab binding
on B-cell sub-populations: CD27
negative B-cells (black line), CD27
positive B-cells (grey histogram) and T-cells (negative control, dotted line) are
shown in (c). The results of the FACS analysis (right graph), showed higher binding capacity of epratuzumab on CD27
negative B-cells compare to
CD27
positive B-cells (P = 0.0002). (d) To study the expression of CD22 on B-cells, PBMCs were stained with a mouse anti-CD22 mAb (Clone S-HCL-1),
which recognizes a different epitope than epratuzumab (n = 5) [16]. The FACS analysis demonstrated that CD22 is more highly expressed on
CD27
negative B-cells compared to CD27
positive B-cells.
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sion of CD22 on T-cells and monocytes as described
by others [4].
Subsequent studies focused in detail on the effects
induced by epratuzumab on particular B-cell subpopula-
tions. Initially, we studied the expression of CD22 on B
cell subsets based on theire x p r e s s i o no fC D 2 7 ,t h e
CD27
negative B-cell subpopulation comprising naïve and
transitional B-cells and the CD27
positive B-cells compris-
ing pre- (IgD
+) and post-switch (IgD
-) memory B-cells
[13].
In this analysis, a substantially higher binding of epra-
tuzumab on CD27
negative B-cells versus CD27
positive
B-cells was observed as shown by a representative histo-
gram in Figure 1c. In fact, there was a two-fold
enhanced anti-CD22 binding to CD27
negative B-cells
(mean fluorescence intensity (MFI) 324.7 ± 74.4) com-
pared to CD27
positive B-cells (MFI 172.9 ± 40.9) (P =
0.0002).
In order to confirm the differential expression of
CD22 on B-cell subpopulations, experiments were
repeated using the mouse anti-human CD22 antibody,
S-HCL-1, which recognizes a different epitope to epra-
tuzumab [16]. These experiments confirmed a higher
CD22 expression on CD27
negative B-cells compared to
CD27
positive B-cells (Figure 1d, n = 5). In summary, spe-
cific binding of epratuzumab on the surface of B-cells
has been confirmed with the highest propensity identi-
fied on CD27
negative B-cells.
Epratuzumab down-modulates CD62L and b7 integrin
surface expression on B-cells
Subsequent studies were designed to identify whether
epratuzumab binding to CD22, known to function as an
adhesion molecule, could modulate the surface expres-
sion of other adhesion molecules on B-cells. Therefore,
CD62L, b7 integrin and b1 integrin surface expression
on PBMCs from SLE patients were studied in vitro after
culture with epratuzumab.
First, the surface expression of CD62L, an adhesion
molecule involved in systemic B-cell activation [19], on
PBMCs was assessed. As shown in Figure 2a (represen-
tative of nine independent experiments using PBMCs
from SLE patients), epratuzumab incubation led to a sig-
nificant down-modulation of CD62L on the surface of
B-cells (P = 0.0078). Thus, CD62L was found to be
expressed on 56.7 ± 16.4% of peripheral B-cells after
incubation without epratuzumab which was reduced to
42.5 ± 12.6% after epratuzumab incubation. Notably,
around 15% of B-cells became negative for CD62L
expression on their surface after epratuzumab incuba-
tion. No significant difference was observed either on
peripheral T-cells or monocytes after epratuzumab incu-
bation (Figure 2a).
Further studies demonstrated that the reduced surface
expression of CD62L was restricted to CD27
negative
B-cells; when this subset was analyzed, 57.9 ± 18.6%
were positive for CD62L in the absence of epratuzumab
(white bar, Figure 2b) and 37.9 ± 15.5% after epratuzu-
mab incubation (grey bar, Figure 2b) (**P =0 . 0 0 4 ;
Figure 2b). However, the frequency of B-cells being
CD62L
positive and CD27
positive remained unaffected by
epratuzumab (48.7 ± 19% versus 44 ± 15.4%).
Additional studies on the expression of the mucosal
adhesion molecule b7i n t e g r i no nC D 2 7
positive and
CD27
negative B-cells are summarized in Figure 2c. Epratu-
zumab incubation induced a significant reduction of the
surface expression of b7i n t e g r i n( P = 0.0039), primarily
confined to CD27
negative B-cells, while no changes were
observed on CD27
positive B-cells. Of note, surface expres-
sion of CD62L and b7 integrin was simultaneously down-
modulated on B-cells after incubation with epratuzumab.
The percentage of CD27
negative B-cells expressing both
CD62L and b7 integrin was significantly decreased after
epratuzumab incubation, from 44.5 ± 16.6% to 28.1 ± 15%
(data not shown). The decrease of both CD62L and b7
integrin on the surface of CD27
negative B-cells suggests that
epratuzumab has the potential to change the adhesion
characteristics of this particular population.
Epratuzumab incubation leads to an increase of b1
integrin surface expression on B-cells
Based on the observed down-modulation of b7i n t e g r i n
surface expression on CD27
negative B-cells by epratuzu-
mab, further analyses focused on the effect of epratuzu-
mab on the expression of the b1 integrin on the surface
of B-cells. In this regard, integrin complexes are com-
posed of b and a subunits and form unique molecules,
and b7 integrin essentially competes with b1i n t e g r i nf o r
the same a4 subunit. A recent study [27] reported that
the surface expression of a4b7 integrin is regulated in a
homeostatic relation with the surface expression of a4b1
integrin on T-cells since high expression of a4b1 integrin
resulted in a loss of a4b7 integrin. With this in mind,
subsequent studies were performed to analyze whether
down-modulation of b7 integrin on the surface of the
CD27
negative B-cells is associated with changes in the
expression of b1 integrin. There appeared to be two
populations of B-cells that, in their basal state, were
either b1 integrin
low or b1 integrin
high as shown in Figure
3. In fact, the data showed that the majority of CD27
positive
B-cells expressed high basal levels of b1i n t e g r i no nt h e i r
cell surface compared with CD27
negative B-cells (Figure 3,
middle and right column). After incubation of PBMCs
with epratuzumab, the percentage of B-cells that were b1
integrin
high increased from 17 ± 7% to 42 ± 10.5% (Figure
3). With regard to CD27
negative B-cells, a significant change
in the proportion of b1i n t e g r i n
high cells was observed after
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human IgG1 control (11.4 ± 6.3%) or without Ig (11.2 ±
3.9%). No difference in the proportion of b1i n t e g r i n
high
cells was observed on CD27
positive B-cells after epratuzu-
mab treatment.
Since fibronectin is one of the ligands for the a4b1
integrin, transwell migration assays using fibronectin-
coated filters were employed as functional tests for spon-
taneous migration. Notably, incubation of B-cells with
epratuzumab provoked enhanced spontaneous transmi-
gration of B-cells (Figure 4) which was seen for CD27
posi-
tive and CD27
negative B-cells. However, the transmigration
was around threefold higher for CD27
negative B-cells com-
pared to a twofold increase for CD27
positive B-cells.
These data suggest that epratuzumab is able to increase
b1 integrin expression on a fraction of CD27
negative B-
cells and this is associated with a substantial increase in
the functional activity of this integrin.
Epratuzumab enhanced migration of B-cells towards
CXCL12
Additional experiments analyzed the effect of epratuzu-
mab on the migration of B cells towards a range of che-
mokines, such as CXCL12, CXCL13 and to CXCR3
ligands. PBMCs from SLE patients were incubated with
or without epratuzumab and allowed to migrate for 90
minutes at 37°C. Notably, epratuzumab further increased
the chemotactic response towards CXCL12 (Figure 5a)
(P = 0.015) but there was no significant change in the
migration towards CXCL13 or CXCR3 ligands (Figure
5a). No influence of epratuzumab was noted on mono-
cytes or T-cells. Furthermore, epratuzumab led to a
more pronounced effect on the migration towards
CXCL12 on CD27
negative B-cells compared to CD27
posi-
tive B-cells (P = 0.0078; Figure 5b). The migration
capacity of both CD27
negative B-cells and CD27
positive
B-cells to CXCL13 and CXCR3 ligands was unaffected
Figure 2 Epratuzumab leads to decreased surface expression of the adhesion molecules CD62L and b7 integrin on CD27
negative B-cells.
Comparison of the surface expression of CD62L on PBMCs from SLE patients with (grey histogram) and without (white histogram) epratuzumab
incubation (a). Monocytes (CD14
positive) showed a moderate but non-significant reduction of CD62L, whereas this expression was not influenced
on T-cells (CD3
positive) by epratuzumab. Notably, epratuzumab led to a significant reduction of the CD62L surface expression on B-cells (P< 0.01).
These comparative studies of CD27
negative B-cells versus CD27
positive B-cells demonstrated that the reduction of CD62L was confined to
CD27
negative B-cells (b) (P< 0.01). Similarly, the surface expression of b7 integrin (c) was significantly reduced by epratuzumab on CD27
negative
B-cells but not on CD27
positive B-cells (** P < 0.01; ns not significant, n = 9).
Daridon et al. Arthritis Research & Therapy 2010, 12:R204
http://arthritis-research.com/content/12/6/R204
Page 6 of 11by incubation with epratuzumab (data not shown).
These data indicate that another consequence of high
CD22 expression on CD27
negative B-cells is increased
migration towards CXCL12 in the presence of
epratuzumab.
Discussion
This study demonstrates that epratuzumab is able to
induce significant functional changes on B-cells in vitro,
particularly of CD27
negative B-cells, which include 1) a
substantial reduction of the cell-surface expression of
Figure 3 Epratuzumab induces b1 integrin on CD27
negative B-cells. In order to analyse changes in the surface expression of b1i n t e g r i no n
B-cell sub-populations (CD27
negative B-cells and CD27
positive B-cells), we incubated PBMCs for 90 minutes at 37°C, 5% CO2 without epratuzumab
(first line), or with human IgG1 (second line) or with epratuzumab (third line) (n = 3). The histograms are representative of three independent
experiments and the results are summarized in Figure 3 (mean ± SEM).
Figure 4 Epratuzumab increases the motility of the B-cells. To evaluate the functionality of b1 integrin on the B-cells, we checked the
capacity of B-cells to transmigrate through fibronectin independently of chemoattractant, with epratuzumab incubation (data from nine
independent experiments are shown in Figure 4). Epratuzumab caused an enhanced transmigration through fibronection layers; indeed, a
threefold greater basal motility of treated CD27
negative B-cells was observed.
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integrin cell-surface expression; and 3) enhanced spon-
taneous migration and directed migration towards
CXCL12. Since such changes were not induced to a
l a r g ee x t e n tb ye p r a t u z u m a bo nC D 2 7
positive B-cells, it
appears plausible that these effects are linked to the
higher CD22 surface expression on CD27
negative B-cells.
Differential binding of epratuzumab to PBMCs
Epratuzumab was found to bind to the highest extent on
CD27
negative B-cells followed by CD27
positive cells. The
competition experiments demonstrated that this binding
is specific via targeting CD22 and a role for Fc receptor
binding could not be demonstrated. This difference
between CD27
negative B-cells and CD27
positive B-cells can
be explained by the higher expression of CD22 which
we observed by FACS analysis and, according to the
data base, CD22 mRNA is also more highly expressed
on CD27
negative naïve B-cells and CD27
negative transi-
tional B-cells than on CD27
positive B-cells (Platform ID:
GPL570, accession no. [GEO:GSE17186]; Human B-cell
subsets).
CD22 is not expressed on monocytes [4,6] but we did
detect a small degree of epratuzumab binding to these
cells consistent with the capacity of monocytes to med-
iate Fc receptor-dependent binding to antibodies [28,29].
Figure 5 Enhanced migration of CD27
negative B-cells from SLE patients towards CXCL12 after epratuzumab incubation. To assess the
migration towards CXCL12, CXCL13 and CXCR3 ligands of PBMCs from eight SLE patients, we performed transwell migration assays after
epratuzumab incubation (10 μg/mL for 90 minutes). The migration of different cell types towards CXCL12 was analyzed by flow cytometry [(T-cells,
CD3
positive), (monocytes, CD14
positive), (total B-cells CD19
positive); CD27
negative B-cells CD27
positve B-cells] and epratuzumab incubation lead to a
significantly enhanced migration of B-cells (a) (*P < 0.05). No effect of epratuzumab was observed on T-cells and on monocytes. Migration of all cell
types, including B-cells, towards CXCL13 and CXCR3 ligands was unaffected by epratuzumab. (b) Studies of CD27
negative and CD27
positive B-cells from
SLE patients revealed that the increased migration toward CXCL12 was primarily restricted to CD27
negative B-cells (** P <0 . 0 1 ) .
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epratuzumab
We observed a number of changes in adhesion molecule
expression on the surface of B-cells under the influence
of epratuzumab, such as a decrease of CD62L on
CD27
negative B-cells. Although the biological conse-
quences of reduced CD62L expression remain to be
delineated, it could potentially result in disturbed
immune activation. Previous studies in CD62L-deficient
mice reported that lymphocyte recruitment into inflam-
matory sites was inhibited significantly, whereas lympho-
cyte recruitment to the spleen was increased [30,31].
These results support the notion that reduced CD62L
expression on B-cells by epratuzumab may disturb
recruitment of B-cells to different sites of inflammation.
As with CD62L expression, epratuzumab incubation
down-modulated b7 integrin surface expression which
was again seen primarily on CD27
negative B-cells. The
interaction of a4b7 integrin with its natural ligand,
MAdCAM-1, is involved in the migration of immune
cells to mucosal tissues. Whether there is a role for
mucosal immune activation in SLE remains a matter of
debate, although enhanced soluble CD14 likely related
to LPS-dependent activation in gut-associated lymphoid
tissues has been identified in the blood of SLE patients
[32], consistent with persistent, enhanced activation of
mucosal immunity.
Because of the apparent striking reductions of b7
integrin expression on CD27
negative B-cells after incuba-
tion with epratuzumab, and the known interdependence
between b1a n db7 integrin expression on human
T-cells which share the a4 integrin subunit [27], the
regulation of b1 integrin expression after epratuzumab
incubation was investigated. Of importance, epratuzu-
mab induced b1 integrin expression on CD27
negative
B-cells while its expression on the surface of CD27
positive
B-cells was already high at baseline and not substantially
changed by epratuzumab. The data indicate that b1
integrin and b7 integrin expression could be regulated
interdependently on CD27
negative B-cells. In addition,
binding to CD22 by epratuzumab provoked the activa-
tion of b1 integrin and resulted in enhanced sponta-
neous migration of both CD27
negative and CD27
positive
B-cells over fibronectin-coated membranes, independent
of any chemokine. Thus, epratuzumab-enhanced b1
integrin expression leads to functionally relevant effects
on B-cells.
Overall, the modification of the adhesion molecule
profile affected preferentially a fraction of CD27
negative
B-cells. In this context, CD27
negative B-cells comprise
two main B-cell sub-populations, transitional B-cells and
mature naïve B-cells [33]. However, we were unable to
distinguish between these two subpopulations in our
experiments. Since expansion of transitional B-cells in
the circulation is correlated with clinical responses
assessed by SLEDAI (Systemic Lupus Erythematosus
Disease Activity Index) [33], further experiments are
warranted to evaluate this hypothesis.
Enhanced migration of CD27
negative B-cells to CXCL12 in
the presence of epratuzumab
Studies conducted to investigate changes on B-cell
migration showed that epratuzumab is able to enhance
the migration of CD27
negative B-cells across gradients of
CXCL12 in vitro. This chemokine has been shown to be
expressed by lymphoid organs [34,35] and inflamed kid-
neys [36,37] and, therefore, may account for enhanced
emigration of CD27
negative B-cells but not memory
CD27
positive B-cells from the peripheral blood observed
clinically in SLE patients treated with epratuzumab [13].
Since epratuzumab binds preferentially to CD27
negative
B-cells, one could speculate that the enhanced migration
of CD27
negative B-cells is due to a stronger effect of
CD22 expression on these cells.
Moreover, the bone marrow produces substantial
amounts of CXCL12, and is able to attract antibody-
secreting cells from the periphery [38]; it also employs
CD22 and b1 integrin for migration and retention of
B-cells to this site [6,11,12,21,23]. If similar mechanisms
apply also for other B cell subpopulations, such as
CD27
negative transitional or CD27
negative naïve B-cells, it
is also possible that these cells become trapped in the
bone marrow and cannot fully differentiate in secondary
lymphoid organs.
Epratuzumab did not influence B-cell migration
towards CXCL13 and CXCR3 ligands using PBMCs
from SLE patients which argues that the migration
changes observed with epratuzumab are not non-speci-
fic. However, we cannot rule out the possibility that the
enhanced migration of CD27
negative B-cells obtained
from SLE patients may reflect the loss of migrating cells
from the peripheral blood during active lupus. In this
regard, it has been reported that levels of CXCL9,
CXCL10 and CXCL11 correlate with lupus disease activ-
ity [39,40]. In addition, CD4
positiveCXCR3
positive T-cells
have been found to be increased in the urine of patients
with lupus nephritis, which may suggest involvement of
this chemokine system [37].
With regard to the current study, a discussion of the
interrelationship between CD22 modulation by epratu-
zumab and changes in adhesion molecule expression
and migration is of importance. Interactions between
intracellular signaling pathways may offer an explana-
tion. In this context, Lyn is known to be the kinase
responsible for phosphorylation of ITIMs on CD22 [41]
and it has been reported that Lyn is of critical impor-
tance in SLE with lower expression of Lyn being typical
for SLE patients [42,43]. In addition, Lyn is closely
Daridon et al. Arthritis Research & Therapy 2010, 12:R204
http://arthritis-research.com/content/12/6/R204
Page 9 of 11related to Syk (Spleen tyrosine kinase) which is involved
in BCR signaling, but also in the regulation of integrin
activation [44]. Moreover, recent work indicates that
Syk is involved in CXCL12- and a4b1 integrin-induced
signaling in chronic lymphocytic leukemia [45]. Further
investigation of CD22-Lyn-Syk interactions could lead
to a better understanding of the precise mechanisms by
which CD22 regulates cell adhesion and migration path-
ways in B cells.
Conclusions
This study demonstrates for the first time that the
humanized anti-CD22 mAb, epratuzumab, displays a
substantially higher degree of binding to CD22 on
CD27
negative B-cells resulting in functional effects such
as enhanced migration towards CXCL12 and modifica-
tion of adhesion molecule cell surface expression
(down-regulation of the expression of CD62L and b7
integrin and up-regulation of b1 integrin). Collectively,
the data suggest that epratuzumab could disturb traf-
ficking of CD27
negative B-cells, which provides an insight
into the potential mechanism of action of this antibody
in SLE.
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